** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket
** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial
** The drug, DA-1726, on average reduced body weight by 4.3%
** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33
** "We anticipate that greater weight loss may be seen in longer duration studies" - co
** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals
** Up to last close, stock had fallen 9.4% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。